Related Experiment Video
Updated: Jun 26, 2025
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Emerging drug profile: JAK inhibitors
Alexander Coltoff1, Andrew Kuykendall2
1Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, USA.
Insights
Janus kinase (JAK) inhibitors help myelofibrosis patients, but resistance limits effectiveness. Combining JAK inhibitors with other therapies shows promise for better and longer responses in treating this bone marrow disorder.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Dysregulated Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling is a key driver in myelofibrosis pathogenesis.
- JAK inhibitors are a cornerstone of first-line therapy, offering benefits in splenomegaly, symptoms, and cytopenias for myelofibrosis patients.
Purpose of the Study:
- To review the role of JAK/STAT signaling in myelofibrosis.
- To explore potential synergistic therapeutic targets and recent advancements in combination strategies involving JAK inhibitors for myelofibrosis treatment.
Main Methods:
- Review of current literature on JAK/STAT signaling in myelofibrosis.
- Analysis of recent phase III clinical trial data for novel combination therapies.
- Discussion of biological rationale for targeting accessory pathways in conjunction with JAK inhibition.
Main Results:
- Single-agent JAK inhibition provides clinical benefits but is often limited by variable or transient responses due to resistance mechanisms.
- Emerging combination strategies involving novel agents added to JAK inhibitors have met primary endpoints in recent phase III trials.
- Ongoing late-stage studies are investigating further advancements in combination therapies for myelofibrosis.
Conclusions:
- Overcoming JAK inhibitor resistance through combination therapy is crucial for improving patient outcomes in myelofibrosis.
- Targeting cooperating signaling pathways synergistically with JAK inhibitors offers a promising strategy to enhance response rates and durability.
- Future research and clinical trials will continue to refine combination approaches for myelofibrosis management.
Abstract:
Dysregulated JAK/STAT hyperactivity is essential to the pathogenesis of myelofibrosis, and JAK inhibitors are the first-line treatment option for many patients. There are four FDA-approved JAK inhibitors for patients with myelofibrosis. Single-agent JAK inhibition can improve splenomegaly, symptom burden, cytopenias, and possibly survival in patients with myelofibrosis. Despite their efficacy, JAK inhibitors produce variable or short-lived responses, in part due to the large network of cooperating signaling pathways and downstream targets of JAK/STAT, which mediates upfront or acquired resistance to JAK inhibitors. Synergistic inhibition of JAK/STAT accessory pathways can increase the rates and duration of response for patients with myelofibrosis. Two recently reported, placebo-controlled phase III trials of novel agents added to JAK inhibition met their primary endpoint, and additional late-stage studies are ongoing. This paper will review role of dysregulated JAK/STAT signaling, biological plausible additional therapeutic targets and the recent advancements in combination strategies with JAK inhibitors for myelofibrosis.
More Related Videos
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF